Falco Appoints Red Cloud to Provide Promotional Services
MONTREAL, April 04, 2024 (GLOBE NEWSWIRE) — Falco Resources Ltd. (TSX.V: FPC) (“Falco” or the “Corporation”) is pleased to announce that […]
Mayfair Gold Sets the Record Straight and Corrects Muddy Waters’ Misleading and Inaccurate Statements
MATHESON, Ontario, April 04, 2024 (GLOBE NEWSWIRE) — Mayfair Gold Corp. (“Mayfair” or the “Company”) (TSX-V: MFG; OTCQB: MFGCF) today […]
GXO Schedules First Quarter 2024 Earnings Conference Call for Wednesday, May 8, 2024
GREENWICH, Conn., April 04, 2024 (GLOBE NEWSWIRE) — GXO Logistics, Inc. (NYSE: GXO) will hold its first quarter 2024 earnings […]
Aduro Clean Technologies Provides Update on Joint Western University Research Project
LONDON, Ontario, April 04, 2024 (GLOBE NEWSWIRE) — Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (CSE: ACT) (OTCQX: ACTHF) […]
ZeroFox Wins Multiple Industry Awards and Reinforces Digital Risk Protection Leadership Position
20th Annual Globee® Awards for Cybersecurity and G2’s 2024 Spring Report honor ZeroFox’s innovative Brand and Domain Protection capabilities WASHINGTON, […]
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Dose escalation in Phase 1b trial completed with no dose-limiting toxicities, no or low-grade cytokine release syndrome and no immune […]
ScottsMiracle-Gro Provides Update on Fiscal 2024 Second Quarter
MARYSVILLE, Ohio, April 04, 2024 (GLOBE NEWSWIRE) — The Scotts Miracle-Gro Company (NYSE: SMG), the world’s leading marketer of branded […]
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Improved […]
Oculis to Participate at Upcoming April Investor Conferences
ZUG, Switzerland and BOSTON, April 04, 2024 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company […]
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
– Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the benefit of enhanced host conditioning, […]
